Compare SD & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SD | ARVN |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 502.8M | 516.2M |
| IPO Year | 2006 | 2018 |
| Metric | SD | ARVN |
|---|---|---|
| Price | $14.33 | $8.98 |
| Analyst Decision | Strong Sell | Buy |
| Analyst Count | 1 | 19 |
| Target Price | $15.00 | ★ $15.05 |
| AVG Volume (30 Days) | 280.8K | ★ 858.7K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | 12.43 | ★ 58.84 |
| EPS | 1.22 | ★ 1.70 |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | $12.65 | N/A |
| Revenue Next Year | $1.75 | N/A |
| P/E Ratio | $11.61 | ★ $5.69 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.10 | $6.97 |
| 52 Week High | $18.45 | $14.22 |
| Indicator | SD | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 56.69 | 54.71 |
| Support Level | $13.85 | $7.90 |
| Resistance Level | $14.34 | $9.65 |
| Average True Range (ATR) | 0.37 | 0.42 |
| MACD | 0.07 | 0.06 |
| Stochastic Oscillator | 80.25 | 60.45 |
SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services. The company's primary areas of operation are the Mid-Continent in Oklahoma and Kansas.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.